Mario Silva1, Carlotta Galeone2, Nicola Sverzellati3, Alfonso Marchianò4, Giuseppina Calareso4, Stefano Sestini5, Carlo La Vecchia2, Gabriella Sozzi6, Giuseppe Pelosi7, Ugo Pastorino5. 1. Section of Radiology, Department of Surgical Sciences, University Hospital of Parma, Parma, Italy; Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: mariosilvamed@gmail.com. 2. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. 3. Section of Radiology, Department of Surgical Sciences, University Hospital of Parma, Parma, Italy; Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 6. Tumor Genomics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 7. Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract
INTRODUCTION: Small cell lung cancer (SCLC) constitutes a distinct component of symptomatic or advanced-stage lung cancers in clinical practice and in lung cancer screening trials. The purpose of this study was to describe the outcome of SCLC in lung cancer screening trials and compare the frequency of SCLC in our cohort with that in the major lung cancer screening trials. METHODS: Subjects with a diagnosis of SCLC were selected from two lung cancer screening trials by low-dose computed tomography (LDCT), and their demographic characteristics, clinical parameters, tumor stage at diagnosis, therapy, and survival times were recorded. Survival curves were estimated using the Kaplan-Meier method. RESULTS: Ten cases of SCLC were reported in 45,141 person-years (22 in 100,000 person-years), representing the 6% of all lung cancer cases. Cumulative tobacco consumption was 82 pack-years compared with 39 and 46 pack-years for the overall study population and subjects with non-SCLC, respectively. Most of the neoplasms were in an advanced stage (seven in stage IV and one each in stages IIIb, IIIa, and Ia). Two subjects were treated with lobectomy for curative purposes and died of diffuse metastasis within 2 years of diagnosis. The median overall survival time in the LDCT arms was 20.6 months, with no survivors remaining at 3 years. CONCLUSIONS: Subjects in whom SCLC develops are a subgroup of smokers with extremely high cumulative tobacco consumption. Consequently, the frequency of SCLC in our population was lower than in other screening populations, with higher cumulative tobacco consumption. Screening for lung cancer by LDCT does not improve survival of SCLC, with no survivors remaining at 3 years after diagnosis.
INTRODUCTION:Small cell lung cancer (SCLC) constitutes a distinct component of symptomatic or advanced-stage lung cancers in clinical practice and in lung cancer screening trials. The purpose of this study was to describe the outcome of SCLC in lung cancer screening trials and compare the frequency of SCLC in our cohort with that in the major lung cancer screening trials. METHODS: Subjects with a diagnosis of SCLC were selected from two lung cancer screening trials by low-dose computed tomography (LDCT), and their demographic characteristics, clinical parameters, tumor stage at diagnosis, therapy, and survival times were recorded. Survival curves were estimated using the Kaplan-Meier method. RESULTS: Ten cases of SCLC were reported in 45,141 person-years (22 in 100,000 person-years), representing the 6% of all lung cancer cases. Cumulative tobacco consumption was 82 pack-years compared with 39 and 46 pack-years for the overall study population and subjects with non-SCLC, respectively. Most of the neoplasms were in an advanced stage (seven in stage IV and one each in stages IIIb, IIIa, and Ia). Two subjects were treated with lobectomy for curative purposes and died of diffuse metastasis within 2 years of diagnosis. The median overall survival time in the LDCT arms was 20.6 months, with no survivors remaining at 3 years. CONCLUSIONS: Subjects in whom SCLC develops are a subgroup of smokers with extremely high cumulative tobacco consumption. Consequently, the frequency of SCLC in our population was lower than in other screening populations, with higher cumulative tobacco consumption. Screening for lung cancer by LDCT does not improve survival of SCLC, with no survivors remaining at 3 years after diagnosis.
Authors: Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin Journal: Nat Rev Clin Oncol Date: 2017-05-23 Impact factor: 66.675
Authors: Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser Journal: Cochrane Database Syst Rev Date: 2022-08-03
Authors: A-M C Dingemans; M Früh; A Ardizzoni; B Besse; C Faivre-Finn; L E Hendriks; S Lantuejoul; S Peters; N Reguart; C M Rudin; D De Ruysscher; P E Van Schil; J Vansteenkiste; M Reck Journal: Ann Oncol Date: 2021-04-20 Impact factor: 51.769
Authors: Yeon Wook Kim; Minhee Jeon; Myung Jin Song; Byoung Soo Kwon; Sung Yoon Lim; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Kyung Won Lee; Jae Ho Lee; Choon-Taek Lee Journal: Transl Lung Cancer Res Date: 2021-11